Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 263

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 263
---
 Key Opinion Leaders (KOLs) at launch.
DiamiR also aims to continue and to expand relationships with key associations, such as Alzheimer’s Association, Alzheimer’s
Drug Discovery Foundation (ADDF), Gates Ventures, and International Rett Syndrome Foundation (IRSF). DiamiR has participated in, and plans
on attending and presenting our work at key symposiums and conferences, such as Alzheimer’s Association International Conference
(AAIC), Clinical Trials on Alzheimer’s Disease (CTAD), AD/PD Alzheimer’s & Parkinson’s Diseases Conference, Child
Neurology Society (CNS) meeting and publish its work in high profile peer-reviewed journals.

Implement a robust commercial strategyaimed
at securing coverage and contracting with Medicare and private payors. Publishing evidence of DiamiR’s tests’ validity and
utility will drive its clinical work which in turn will power DiamiR’s reimbursement efforts.

Work closely with licensing and regulatory agencies to ensure that clinical validity and utility of the tests satisfy all necessary requirements and quality control standards.
These include maintaining licenses with States department of Health, CLIA and College of American Pathology (CAP).

Build a pipeline/portfolio of early detection and risk assessment tests in Brain health and other indications, including tests for Rett syndrome, and gastrointestinal (GI) and
pulmonary (lung) cancers.

In addition to DiamiR’s CogniMIR test for AD, it is developing
a miRNA-based assay for monitoring of progression and severity of Rett Syndrome; a panel of blood protein biomarkers for MCI and AD; a
blood-based miRNA test for Glioblastoma, an aggressive form of brain cancer; and miRNA panels for lung and GI malignancies.

The following table sets forth the current clinical
status and next development steps for DiamiR’s current “lead products,” along with the date DiamiR currently believes
it will complete such next step towards launching the tests in clinical practice setting.

| Product/Indication                         |     | Status                           |     | Next Step                   |     | Estimated Completion 
 Date of Next Step(1) |
| APOE Genotyping Test/AD(2)                 |     | Validated                        |     | Ready for commercial launch |     | Completed            |
| CogniMIR®/MCI & AD                         |     | Test Optimization                |     | Clinical Validation Study   |     | 1H 2026              |
| RETT Syndrome Test                         |     | Clinical Validation